A surprise FDA advisory panel imperils Fibrogen’s experimental anemia pill
Roxadusat is a potential blockbuster medicine, representing a new way to treat anemia suffered by kidney disease patients with a pill.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
All Coverage
advertisement
